Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"We are very fortunate to have exceptional scientists leading our Flow Cytometry Services," says Tony Lialin, Chief Commercial Officer at Invivoscribe. "Our hematopathologists are domain experts that have an intimate understanding of hematologic malignancies, the markers, and the instrumentation gained from their decades of experience. When we were developing our flow assays we had three goals: (1) to provide partners with one-stop international screening and MRD testing, (2) to leverage our infrastructure to quickly develop panels to meet novel partner needs, and (3) to provide standardized CAP/CLIA testing in all of our ISO 15189 accredited global laboratories. We are excited about our unique offering in Asia and we are well-positioned to help our pharma partners accelerate clinical studies and approval of their novel therapies worldwide."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SAN DIEGO -- Businesswire -- Today Invivoscribe, a global leader in precision diagnostics, announced the launch of a new 12-color multiparametric flow cytometry service in Shanghai, China, the newest reference laboratory in their international LabPMM network. Flow cytometry has long been the standard of care for many blood cancers including acute myeloid leukemia (AML), but to achieve minimal residual disease (MRD) level sensitivity with limited specimen, powerful 12-color multiparametric flow cytometry (MFC) is needed. By providing the combination of 12-color flow cytometry and next-generation sequencing (NGS) MRD capabilities in the US, in Europe, and also in China, Invivoscribe now offers a comprehensive international solution for our pharma partners.
Invivoscribe’s globally standardized network of LabPMM reference laboratories offer best in class NGS assays, gene panels, and bioinformatics software, to complement our new MFC panels. The addition of 12-color MFC panels to our existing NGS capabilities, eliminates the need to split primary subject specimens and have them tested in multiple labs. It also allows the same pull of bone marrow to be tested using several complementary technologies, so pharma partners can obtain and compare results leveraging limited samples using targeted assays and technologies for drug development and clinical studies. By offering both MFC and NGS testing in our international laboratories, Invivoscribe can accelerate clinical trials and streamline drug approvals.
“We are very fortunate to have exceptional scientists leading our Flow Cytometry Services,” says Tony Lialin, Chief Commercial Officer at Invivoscribe. “Our hematopathologists are domain experts that have an intimate understanding of hematologic malignancies, the markers, and the instrumentation gained from their decades of experience. When we were developing our flow assays we had three goals: (1) to provide partners with one-stop international screening and MRD testing, (2) to leverage our infrastructure to quickly develop panels to meet novel partner needs, and (3) to provide standardized CAP/CLIA testing in all of our ISO 15189 accredited global laboratories. We are excited about our unique offering in Asia and we are well-positioned to help our pharma partners accelerate clinical studies and approval of their novel therapies worldwide.”
Leveraging an international network of our wholly-owned clinical reference laboratories, Invivoscribe can rapidly design and validate custom panels, track MRD for a range of oncologic diseases, including solid tumors, and develop and commercialize companion diagnostic assays for pharma partners.
About Invivoscribe
Invivoscribe® has been Improving Lives with Precision Diagnostics® for more than twenty-five years, advancing the field of precision medicine by developing and selling standardized reagents, tests, and bioinformatics tools to more than 700 customers in 160 countries. Invivoscribe also has a significant impact on global health working with pharmaceutical companies to accelerate approvals of new drugs and treatments by supporting international clinical trials, developing, commercializing companion diagnostics, and providing expertise in both regulatory and laboratory services. With its proven ability to provide global access to distributable reagents, kits, and controls, as well as clinical trial services through our international clinical lab subsidiaries (LabPMM®), Invivoscribe has demonstrated it is an ideal partner. For additional information please contact Invivoscribe at businessdevelopment@invivoscribe.com or visit us at www.invivoscribe.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005914/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Invivoscribe, Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 삼성전자, AI PC ‘갤럭시 북4 엣지’ 국내 출시 - 뉴스와이어
- 가평읍 주민자치센터 드럼 버스킹, 페스티벌의 새로운 장이 되다 - 뉴스와이어
- 대한전선, 미국서 1300억원 수주 쾌거… 주요 공급자로 입지 강화 - 뉴스와이어
- 장재훈 현대차 사장, 수소위원회 공동의장 취임 - 뉴스와이어
- GS25, 힙걸리 프로젝트 6탄 ‘뉴룩 막걸리’ 출시… 제로당·절반 칼로리 등 흥행 공식 총망라 - 뉴
- 아카라라이프, 혁신적인 스마트홈 제어 방식을 지원하는 첫 번째 패널 스위치 ‘매직패드 S1 Plus
- HD현대중공업, 필리핀 초계함 ‘미겔 말바르함’ 진수 - 뉴스와이어
- 씨코, 부천국제판타스틱영화제 ‘세기의 혈전’ 티켓 사전예매 단독 오픈 - 뉴스와이어
- 동아제약, 어린이 벌레물림연고 ‘디판버그겔’ 출시 - 뉴스와이어
- 베일러국제학교, 안성 캠퍼스 매입 완료와 함께 입학 설명회 개최 - 뉴스와이어